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S U M M A R Y
Vaccination is an effective preventive measure that has been used in the unique Hajj pilgrimage setting
to control the transmission of infectious diseases. The current vaccination policy applied during Hajj is
reviewed herein, highlighting the effectiveness of the approaches applied and identifying research gaps
that need to be ﬁlled in order to improve the development and dissemination of Hajj vaccination
strategies.
 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hajj is a unique mass gathering event associated with increased
risks to public health within the host country (Kingdom of Saudi
Arabia, KSA) and globally. The associated infectious disease
hazards include the dissemination of airborne infections, food-
borne disease, blood-borne diseases, and zoonotic infections.1
Vaccination is one of the major preventive measures used to
prevent infections and control the transmission of infectious
diseases. Vaccination has reduced the overall global morbidity and
mortality associated with many infectious diseases, with the
World Health Organization (WHO) estimating that 2.5 million lives
a year are protected from infections.2 Moreover, some vaccines
confer protection not only to the vaccinated individuals but also
to unvaccinated contacts, contributing to the development of
community protection or herd immunity.3 In addition, there is
increasing evidence that bacterial and viral vaccines may have
an impact on controlling the emergence and dissemination of
antimicrobial resistance.4–6
Currently, licensed vaccines can be categorized into ﬁve main
types: inactivated, live attenuated, subunit, toxoid, and conjugate* Corresponding authors.
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creativecommons.org/licenses/by-nc-nd/4.0/).vaccines (Table 1). The type of vaccine determines its mode of
action, including the prevention of pathogen transmission,
inhibition of pathogen persistence and multiplication, or a
reduction in disease progression and severity.7
The current Hajj vaccination policy includes mandatory
vaccination for all pilgrims against meningococcal disease.8,9 This
is in addition to mandatory vaccination against yellow fever and
polio for pilgrims coming from endemic regions.10 The Saudi
Ministry of Health strongly recommends seasonal inﬂuenza
vaccination for all pilgrims, particularly those at high risk of
infection complications.8,9
The impact of the current vaccination policy on the control of
infectious disease transmission in this unique setting of the Hajj
pilgrimage is reviewed herein. Furthermore, how research can
determine the elements of future Hajj vaccination strategies is
discussed, and the research gaps in current knowledge required to
improve the development and dissemination of vaccine strategies
are identiﬁed.
2. Features of the preferred Hajj vaccines
A number of issues need to be addressed carefully before the
introduction of a new vaccine for use during Hajj. Key aspects
include the type of immune response induced by the vaccine, the
efﬁcacy of the vaccine among extremely varied populations
(including different age groups, prior exposure to infectiousious Diseases. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Vaccine availability for Hajj-associated diseases (FDA-approved only)
Health hazards at Hajj Infectious agent Vaccine Manufacturer Vaccine type Administration Approved for persons
aged:
1. Airborne Neisseria
meningitidis
Menomune Sanoﬁ Inactivated (A/C/Y/
W135, polysaccharide)
SC 2 years
Menactra Sanoﬁ Inactivated (A/C/Y/
W135, conjugate
diphtheria toxoid)
IM 9 months–55 years
Menveo GlaxoSmithKline Inactivated (A/C/Y/
W135) conjugate
(diphtheria CRM197)
IM 2 months–55 years
Bexsero GlaxoSmithKline Recombinant IM 10–25 years
Trumenba Pﬁzer Recombinant IM 10–25 years
Streptococcus
pneumoniae
Pneumovax 23 Merck Inactivated (23-valent
polysaccharide)
IM or SC 2 years at high risk and
adults >50 years
Prevnar 13 Pﬁzer Inactivated (13-valent)
conjugate (diphtheria
CRM197)
IM 6–17 years and adults
>50 years
Inﬂuenza virus Fluarix GlaxoSmithKline Inactivated (A and B
serotypes)
IM 3 years
FluLaval GlaxoSmithKline Inactivated (A and B
serotypes)
IM 3 years
Fluvirin Novartis Inactivated (A and B
serotypes)
IM 4 years
Agriﬂu Novartis Inactivated (A and B
serotypes)
IM 18 years
Flucelvax Novartis Inactivated (A and B
serotypes)
IM 18 years
Fluzone Sanoﬁ Inactivated (A and B
serotypes)
IM 6 months
Fluzone (intradermal) Sanoﬁ Inactivated (A and B
serotypes)
ID 18–64 years
Fluzone (high-dose) Sanoﬁ Inactivated (A and B
serotypes)
IM 65 years
Aﬂuria bioCSL Inactivated (A and B
serotypes)
IM 5 years
Flublok Protein Science
Corporation
Recombinant IM 18 years
FluMist Medimmune Live attenuated IN (spray) 2–49 years
2. Food-borne
and enteric
Poliovirus Sabin OPVa Live attenuated Oral
IPOL Sanoﬁ Inactivated SC or IM 6 weeks
Hepatitis A virus Havrix GlaxoSmithKline Inactivated IM 1 year
Vaqta Merck Inactivated IM 1 year
Rotavirus Rotateq Merck Live (pentavalent) Oral 6–12 weeks
Rotarix GlaxoSmithKline Live (pentavalent) Oral 6–24 weeks
Vibrio choleraea Dukoral Valneva Inactivated with
recombinant CTB
Oral 2 years
Shanchol Shantha Inactivated bivalent
O1/O139
Oral 1 year
Salmonella Typhi Vivotif Crucell Live attenuated Ty2 Oral 6 years
Typhim Vi Sanoﬁ Inactivated IM 2 years
Diarrhoeagenic
Escherichia coli
NA
Shigella spp NA
3. Blood-borne Hepatitis B virus Engerix-B GlaxoSmithKline Recombinant (all HepB
serotypes)
IM All ages
Recombivax-HB Merck Recombinant (all HepB
serotypes)
IM All ages
Twinrix GlaxoSmithKline Inactivated/
recombinant (HepA–
HepB)
IM 18 years
Hepatitis C virus NA
HIV NA
4. Vector-borne Yellow fever virus YF-Vax Sanoﬁ Live attenuated SC 9 months
FDA, US Food and Drug Administration; NA, no commercial vaccine is available; SC, subcutaneous; IM, intramuscular; ID, intradermal; IN, intranasal; CTB, Cholera Toxin B subunit.
a Not currently FDA-approved, but included for completeness.
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transmission of disease, the impact of vaccine types on circulating
microbial genomes (risk of emergence of vaccine escape variants),
and any indirect effects on the circulation of antimicrobial-resistant
elements. Vaccination strategies in the Hajj setting should carefully
address these aspects and emphasize the potential impacts from
the immunological (e.g., efﬁcacy and safety among different age
groups), epidemiological (e.g., changes in transmission patterns),and evolutionary (e.g., changes in pathogen population structure)
perspectives.
Importantly, the innate and acquired immune responses are
weaker at younger ages and also decline with age, leading to the
impaired persistence of antibody responses and the development
of lower levels of serum antibodies to both protein and
polysaccharide vaccines.7 Therefore, age-associated changes in
the immune response impact the efﬁcacy of these particular types
Table 2
Potential mandatory vaccines for Hajj and outstanding questions
Infectious agent Vaccine type Outstanding questions
Neisseria meningitidis Conjugate? Carriage and transmission reduced by using conjugate vaccines?
Schedule of vaccination?
Time required to elicit an immune response to eliminate meningococcal carriage?
Impact on the emergence of novel variants?
Streptococcus pneumoniae High valency
conjugate or combined
(polysaccharide and conjugate)?
Carriage and transmission reduced by using conjugate vaccines?
Impact of escape mutants?
Inﬂuenza virus Inactivated For pilgrims from winter countries only?
Increased effectiveness from universal vaccine?
Cost-effectiveness—against both inﬂuenza and secondary bacterial pneumonia?
Poliovirus Inactivated IPV only?
Hepatitis A virus (HAV) Inactivated Mandatory for non-immune pilgrims?
Cost effectiveness for combined HAV and HBV vaccine?
Schedule of vaccination?
Hepatitis B virus (HBV) Recombinant Mandatory for non-immune pilgrims?
Cost effectiveness for combined HAV and HBV vaccine?
Schedule of vaccination?
Rotavirus Live attenuated (pentavalent) Effectiveness in adult pilgrims?
Vibrio choleraea Inactivated with recombinant CTB Recombinant CTB reduces ETEC infection prevalence?
Indirect impact on the transmission of antimicrobial resistant E. coli?
Cost effectiveness?
Salmonella Typhi Inactivated
Yellow fever virusa Live attenuated
IPV, inactivated polio vaccine; CTB, Cholera Toxin B subunit; ETEC, enterotoxigenic Escherichia coli.
a Endemic countries only.
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also characterized by signiﬁcant diversity in ethnic origin, which
may also impact their susceptibility/resistance (e.g., inﬂuenza
virus-speciﬁc severity alleles) to particular pathogens and to
vaccine-induced immune responses.
In addition, vaccines can induce the emergence of novel
variants of particular pathogens through Darwinian selection
pressures. Pathogens that this has been seen with include viruses
(inﬂuenza) and bacteria (Neisseria meningitidis,11–16 Streptococcus
pneumoniae,17 and Bordetella pertussis18). These changes within the
pathogen population due to vaccine-induced selection can occur at
both the host level and the community level.19 Large-scale studies
are needed to examine the evolutionary consequences of different
vaccine introductions into the Hajj setting, with a particular
model in the near-future being the introduction of pneumococcal
conjugate vaccines with limited valences. These evolutionary
studies will need to address not only the vaccine escape variants
but also the structural changes in virulence factors that lead to the
emergence of variants of novel virulence potential.
It is important to highlight that many vaccines protect
vaccinees from the disease but do not necessarily prevent the
vaccinee from becoming infected by the pathogen (leading to
pathogen colonization/carriage) and therefore acting as a trans-
mitter. The ideal vaccine proﬁle to be used in the Hajj setting would
be one that impacts the transmission of the pathogen itself through
a reduction in the amount and/or duration of carriage by vaccinees.
3. Impact of changing vaccine policy on disease transmission
3.1. Current status reﬂects a success story—the containment of Hajj-
associated meningococcal disease
The Hajj pilgrimage has been associated with two major
outbreaks of bacterial meningitis caused by N. meningitidis
serogroups A and W135, resulting in the global dissemination of
meningococcal disease in 198720,21 and 2000,22,23 respectively. In
response to the ﬁrst outbreak, the Saudi Ministry of Health
introduced the ﬁrst mandated vaccination policy, with all pilgrims
being required to receive the polysaccharide bivalent (A, C)
meningococcal vaccine from 1988 onwards.20 However, thisbivalent vaccine lacked the capability to prevent the nasopharyn-
geal carriage of N. meningitidis and therefore a subsequent
outbreak of serotype A was seen in the UK and was associated
with returning pilgrims and their contacts, particularly children.24
This, combined with the outbreak of serotype W135 in 2000,25 led
to the introduction of a new vaccination policy in 2001 that
mandated quadrivalent meningococcal vaccine (ACYW135) at
least 10 days prior to travelling for the pilgrimage as a requirement
for granting a Hajj visa.22
Recently, studies have suggested that the newly licensed
conjugate vaccines have signiﬁcant advantages over the previous
polysaccharide ones. These include longer lasting immunity26,27
and, more importantly, the ability to reduce the asymptomatic
carriage of N. meningitidis.28,29 The introduction of such vaccines
into the Hajj setting would have a signiﬁcant impact on the risk of
meningococcal disease dissemination by interrupting the trans-
mission of N. meningitidis from pilgrims returning to their home
countries colonized with the bacteria. However, before the
quadrivalent conjugate vaccine becomes the mandated vaccine
for Hajj, more comprehensive studies are required to answer
questions such as the efﬁcacy of the vaccine among groups of
different ages and ethnic origins, and the time required for
vaccinees to become fully protected against both invasion and
colonization. Data so far suggest that the conjugate vaccine
efﬁciently reduces N. meningitidis carriage.29 Carriage was found to
be reduced in UK university students only 2 months after the
vaccine had been administered, and this probably represents the
time required for the immune response to eliminate meningococ-
cal carriage.29 For the meningococcal vaccines, as with all vaccines
used at the Hajj, the important outstanding question of the
potential impact of vaccine escape mutants also needs further
investigation.
3.2. Pros and cons of the introduction of new Hajj vaccinations
3.2.1. Pneumococcal vaccines
Pneumonia is one of the major causes of hospital admission
during Hajj.30 Many studies have identiﬁed S. pneumoniae as the
main etiological agent of lower respiratory tract infections during
the pilgrimage.31–34 Globally, S. pneumoniae causes 14.4 million
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800 000 deaths per year.35
There is also increasing evidence that respiratory viral
infections, particularly inﬂuenza, enhance both the susceptibility
to and severity of subsequent (secondary) bacterial infections
including those with S. pneumoniae.36–38 Modelling studies have
demonstrated a 100-fold increased risk of pneumococcal pneu-
monia following inﬂuenza virus infection.39
The currently available commercial pneumococcal vaccine types
include a 23-valent polysaccharide vaccine (PPV23) and 7-valent
(PCV7) and 13-valent (PCV13) conjugate vaccines. The United States
Advisory Committee on Immunization Practices (ACIP) recom-
mends PPV23 for adults over age 65 years and adults aged 19–64
years with immunocompromising or chronic medical conditions,
including smokers. ACIP also recommends further vaccination with
PCV13 for all immunocompromised adults and immunocompetent
adults with cerebrospinal ﬂuid leaks and/or cochlear implants.
PCV13 is approved for use in children aged 6 weeks and over
and ACIP recommends its use in all children aged 2 months and
over.40–42 Although PPV23 is not highly immunogenic in chil-
dren,43–45 it does confer short-lived protection in adults by
preventing invasive disease.46–53 Multiple studies have shown that
the pneumococcal conjugate vaccines are more effective than the
polysaccharide vaccine in preventing invasive and non-invasive
infections in children less than 5 years old54–57 and adults (>65
years old)58,59 and for preventing pneumococcal disease in
immunocompromised patients.60,61
Many studies have highlighted the impact of pneumococcal
conjugate vaccination on disease incidence and a reduction in
vaccine-serotype carriage (leading to a reduction in disease
transmission).62–66 Serotype switching of S. pneumoniae coupled
with the expansion of non-vaccine strains was ﬁrst identiﬁed in the
USA shortly after the introduction of the PCV7 vaccine in 2000.67,68
Whole-genome sequencing of 62 isolates from the US national
monitoring programme identiﬁed simultaneous recombination in
the S. pneumoniae genome resulting in the widespread emergence
of vaccine escape variants.17
In addition, recent studies using mouse models have demon-
strated limited efﬁcacy of pneumococcal conjugate vaccines for
protecting against secondary pneumococcal infections following
inﬂuenza.69,70 Additional therapeutic strategies should therefore
be considered to prevent secondary pneumococcal infections
associated with inﬂuenza.
Currently, the pneumococcal vaccination is not mandatory for
Hajj, however the polysaccharide pneumococcal vaccine is
strongly recommended for adults >65 years of age. The decision
to include pneumococcal vaccination for all pilgrims as a
mandatory requirement for Hajj requires further comprehensive
studies to address a number of issues. These include the type of
vaccine to be used (polysaccharide, conjugate, or both), vaccina-
tion schedule, timing of vaccination, use of pneumococcal vs.
inﬂuenza vaccine, and most importantly the potential impact of
the widespread usage of such vaccines on selection pressure.
3.2.2. Seasonal inﬂuenza vaccines
There is considerable and growing evidence that inﬂuenza is a
common health hazard for Hajj pilgrims,71 but an accurate
estimate of the overall incidence of inﬂuenza virus infection
during Hajj is not yet available. The prevalence of inﬂuenza virus-
associated infections varies according to the methodology used for
viral characterization, with the highest rate (38%) detected when
surveillance is based on serology and lowest when molecular and
culture-based studies are performed (6%).72–76 A few studies have
found only a low incidence of inﬂuenza A(H1N1)pdm09 and
seasonal A(H3N2) strains among pilgrims77 and healthcare work-
ers employed during Hajj,78 and it is generally felt that this lowincidence was due to the use of vaccination and other control
measures applied by the Saudi health authorities. Even during the
A(H1N1) pandemic in 2009, the prevalence of the pandemic strain
among the arriving and departing pilgrims remained very low.77
The impacts of vaccination, recommended by the WHO as the
most effective way to control inﬂuenza, particularly severe illnesses,
have been addressed in the Hajj setting. However, the outcomes
from studies to date have been inconsistent. For instance, very low
prevalence rates of inﬂuenza A(H1N1)pdm09 (0%) and A(H3N2) (1%)
were seen among vaccinated Egyptian pilgrims,79 while relatively
high prevalence rates of 11% were detected among vaccinated
Iranian pilgrims.80 The analysis of retrospective data covering the
period from 2005 to 2014 suggested a decreasing prevalence of
inﬂuenza among the vaccinated Hajj pilgrims.81 Further large-scale
studies employing integrated genetic, phenotypic, and evolutionary
approaches are required to conﬁrm this ﬁnding.
An additional complexity with inﬂuenza viruses is their ability
to undergo rapid antigenic evolutionary changes (drifts) that
require the reformulation of the vaccine every year to accommo-
date the currently circulating viral strains.82,83 However, the
selection of the strains to be included in the vaccine is usually
based on surveillance of the nucleotide sequences of the viral
neuraminidase (NA) and haemagglutinin (HA) genes.84–88 Recent-
ly, the analysis of whole-genome sequencing data derived from of a
global collection of 3969 A(H1N1) and 4774 A(H3N2) strains
circulating in the period between 2009 and 2015 demonstrated
precedential amino acid changes (481 and 533 sites were
identiﬁed in A(H1N1) and A(H3N2), respectively).89 Moreover,
the majority of these changes are not included in the seasonal
inﬂuenza vaccines. This might partially explain the variation
detected in the efﬁcacy of the seasonal inﬂuenza vaccines from one
year to another.90–93 Similarly, the analysis of global epidemiologi-
cal data covering the period between 2003 and 2015 demonstrated
that there is a mismatch between the vaccine strain choices and
the circulating strains, which are likely to impact Hajj pilgrims.94
The efﬁcacy of the inﬂuenza vaccine is reduced in older people
(>50 years old), who are also the most susceptible group to some of
the severe complications of infection with the virus.95–97 There is
some evidence that increasing the vaccine dosage is still safe and
induces a stronger immune response in adults aged 50–64 years98
and elderly people (>65 years old).99–102
Therefore, both of the commercially available inﬂuenza vaccine
types, inactivated and live attenuated, require regular updating to
match the newly emerging strains. In addition, their impact on the
prevention and the control of inﬂuenza transmission is not
completely clear. A clear requirement for Hajj pilgrims to receive
inﬂuenza vaccination routinely may need to await the develop-
ment of universal vaccines that target more conservative viral
antigens among all inﬂuenza A viruses to reduce this strain
mismatching issue and the logistical issues of offering multiple
doses of such strain-matched vaccines before each Hajj. Recently,
major progress has been achieved in the development of these
universal vaccines using recombinant adenoviruses as vectors.103
A few studies have shown that such vaccine candidates confer
considerable protection against inﬂuenza and, more importantly,
reduce virus transmission in a mouse model.104,105
As noted above, of potentially more importance may be the
indirect beneﬁt of inﬂuenza vaccination on the prevention of
subsequent bacterial pneumonia. A recent study demonstrated
that live attenuated inﬂuenza vaccines, but not conjugate
pneumococcal vaccines, signiﬁcantly reduced both the density
and duration of pneumococcal carriage in mice.70
Finally, a recent study showed that interferon-induced trans-
membrane (IFITM) protein family members can restrict the
replication of pathogenic viruses.106 In particular, IFITM3 is
required to defend the host against inﬂuenza A virus infection
M. Abd El Ghany et al. / International Journal of Infectious Diseases 47 (2016) 29–37 33and could be used as a genetic marker for mediating resistance to
inﬂuenza A infections.106 People with the minor IFITM3 allele
(SNPrs12252-C) are susceptible to severe inﬂuenza infections
requiring hospitalization.106 The distribution of this allele varies
among different ethnic populations. Therefore the efﬁcacy of the
inﬂuenza vaccine and the cost-beneﬁts of protecting populations
are likely to be affected by the ethnic origin of pilgrims and need
more investigation.
3.2.3. Viral hepatitis vaccines
Hepatitis is a travel-associated health risk.107 An assessment of
viral hepatitis risks associated with Hajj is not yet available. However,
Hajj conditions (low food hygiene standards, sharing common
toilets) and pilgrim behaviours associated with ritual activities
(share/reuse  of razor blades for head shaving mandatory for men,
improper disposal of razor blades, cuts when sacriﬁcing animals)
increase food-borne (hepatitis A virus (HAV) and hepatitis E virus
(HEV)), as well as blood-borne (hepatitis B virus (HBV) and hepatitis
C virus (HCV)) hepatitis risks, respectively.108–110 Importantly, KSA
is located within the hepatitis B high–intermediate region (hepatitis
B surface antigen (HBsAg) seroprevalence 5–7%)111 and hepatitis C
high region (antibody to hepatitis C virus (anti-HCV) seroprevalence
3.5%),107,112 with the prevalence of HBV and HCV in blood donors
identiﬁed as 5%113 and 4.3%,114 respectively. In addition, the majority
of the pilgrims come from countries endemic for viral hepati-
tis.111,112,115 For instance, high HBV prevalence rates are seen in
countries from where a large proportion of pilgrims originate: Nigeria
15%, Egypt 10.1%, Turkey 6.6%, and Indonesia 4%.110
There is evidence that previously exposed adults from HAV
endemic regions in Africa, Asia, and South America have life-long
immunity against repeat infection.116,117 In contrast, pilgrims from
non-HAV endemic regions such as Europe, USA, Canada, and
Australia are susceptible to infection. Currently, potent vaccines
against HAV and a combined HAV/HBV vaccine are commercially
available. The WHO states that inactivated hepatitis A vaccines
have a long-lasting protective efﬁcacy of 90–95% in both children
and adults.117 The two-dose vaccination schedule is preferred, but
one dose also induces similar responses.117 HAV vaccination
should be considered for any children from HAV endemic areas and
for the highly susceptible population from non-endemic regions.
Vaccination against HBV remains the most effective measure to
prevent HBV infection,118,119 with the WHO recommending the
addition of the vaccine to all national immunization programmes
globally in 1997.120 In addition the WHO recommends vaccination
of non-immune travellers to moderate/high HBV endemic
countries.121,122
Therefore, HBV vaccination should be considered as a mandatory
Hajj vaccine for all non-immune pilgrims. The standard HBV
vaccination schedule requires three doses administered at 0, 1, and
6 months. However, an accelerated vaccination schedule that
includes three doses within 21 days (at 0, 7, and 21 days) together
with a booster at 12 months has been shown to confer adequate
seroprotection (antibody to hepatitis B surface antigen (anti-HBs)
titre >10 mIU/ml).123 A study comparing the accelerated and
standard vaccination schedules in healthcare workers found that
both schedules induced seroprotection-neutralizing responses after
30 days.124 The use of the booster dose is still a matter of debate.125
A combined vaccine against HAV and HBV may be the best choice
for non-immune pilgrims, as this vaccine has been shown to be as
immunogenic as the monovalent vaccines.126,127
3.3. Preparing for future risks
3.3.1. Polio
Currently, pilgrims from polio endemic countries (where wild
poliovirus is still being transmitted) and polio reinfected countries(with either transmission of imported wild poliovirus or vaccine-
derived poliovirus) should be vaccinated against poliovirus at least
6 weeks before their departure on the pilgrimage and additionally
receive a further dose of oral polio vaccine (OPV) upon arrival.8
This policy appears to have been working effectively as there have
been no recorded cases of poliovirus transmission during the Hajj
to date.
Currently, two vaccines are used to protect against poliovirus,
the inactivated Salk vaccine (IPV) and the oral live attenuated Sabin
(OPV) vaccine. Both vaccines are highly effective in the prevention
of poliomyelitis (paralytic polio) caused by the three serotypes of
poliovirus (WPV1, 2, and 3), but OPV is also effective in preventing
the transmission of poliovirus. Although OPV is the vaccine of
choice to be used in routine immunization and the containment
of outbreaks in polio endemic and non-endemic regions due to its
ability to prevent virus transmission,128 on rare occasions OPV
strains may mutate and revert to the virulent proﬁle of wild
poliovirus (vaccine-associated paralytic polio).129 The vaccine-
derived virus is also capable of genetic change to allow it to either
circulate in the community if a population is under-immunized
(circulating vaccine-derived poliovirus, cVDPV), undergo pro-
longed replication and excretion by immunocompromised vaccine
recipients (immunodeﬁciency-related vaccine-derived poliovirus,
iVDPV), or be present in environmental or sewage sources where
its origin is ambiguous (ambiguous vaccine-derived poliovirus,
aVDPV). These vaccine-derived viruses have been variably
responsible for 25 polio outbreaks in 21 countries during the
period between 2000 and 2015.128
Since the launch of the Global Polio Eradication Initiative, both
types of vaccine have been used globally and have led to a
signiﬁcant drop in polio cases from 350 000 in 1998 to 66 as of
December 2015, with only Afghanistan and Pakistan still being
polio endemic countries.130 The Global Commission for the
Certiﬁcation of Poliomyelitis Eradication (GCC) announced the
eradication of WPV2 in September 2015 with the last case being
reported in 2012.131 Currently, only WPV1 is still transmitted,
while the last WPV3 case was detected in 2012.131,132 Importantly,
cVDPV serotype 2 was responsible for 97% of cVDPV-associated
cases (n = 686) reported in the period between 2006 and 2015.128
The WHO has set a target for a polio-free world (global eradication)
in 2018,133 and in order to avoid the potential occurrence of VDPV-
associated outbreaks, it has strongly recommended that OPV be
phased out and removed in the long term. The ﬁrst step is a switch
from trivalent (tOPV) to bivalent (bOPV1,3) OPV from April 2016,
with the introduction of at least one dose of IPV into all routine
immunization programmes by the end of 2015.134,135
This is a challenging situation and requires that routine
environmental surveillance be conducted to evaluate the occur-
rence of VDPV in sewage samples, particularly in the locations
frequently visited by pilgrims.
3.3.2. Enteric infection and antimicrobial resistance
Gastroenteritis and diarrhoea are common in the mass
gathering and travelling settings. Hajj has been associated with
Vibrio cholerae outbreaks in the past.1 Infectious agents associated
with diarrhoea include bacteria (diarrhoeagenic Escherichia coli,
Salmonella spp, Shigella spp, and Campylobacter spp), viruses
(rotavirus, norovirus, adenovirus, astrovirus), and parasites
(Cryptosporidium spp, Giardia lamblia, and Entamoeba histolytica).
Currently two inactivated oral cholera vaccines (OCV), Dukoral
and Shanchol (Table 1), are available; these have been used mainly
by travellers. Both vaccines confer short-term protection: 79–86%
for 3–6 months in the case of Dukoral136–139 and 87% for over
6 months for Shanchol.140 The vaccination of pilgrims from
cholera-affected countries is extremely important, as it can help to
prevent the transmission of the disease to the host country. This is
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cholera transmission.141,142 In addition, Dukoral has been shown to
confer signiﬁcant short-term protection against enterotoxigenic E.
coli, the predominant bacterial agent associated with Hajj
diarrhoeal infections.143
Modelling has been used recently to assess the impact of
medical interventions (bacterial screening, chemoprophylaxis, and
vaccination) on preventing cholera importation from endemic
settings.144 Chemoprophylaxis has been shown to have a superior
impact over vaccination in terms of protection and associated cost.
However a potential negative impact of this approach, that
prevents its usage in the Hajj setting, is the development of
antimicrobial-resistant variants.145
Recently, the WHO reported on the global status of antimicro-
bial resistance and found high levels of resistance in all regions.
Importantly, bacterial agents including E. coli, non-typhoidal
Salmonella (NTS), and Shigella spp were frequently among the
most likely bacterial species to have acquired antimicrobial
resistance.146 This increases the risk of the Hajj pilgrimage also
fuelling the emergence and dissemination of antimicrobial enteric
pathogens.147
The increasing use and misuse of antimicrobials by Hajj
pilgrims may already be providing selection pressure for bacteria.
A knowledge, attitudes and practice (KAP) survey on antimicrobial
use conducted among Australian pilgrims (n = 229) during the
2013 Hajj season, found that the majority of the pilgrims surveyed
had been taking antibiotics without prescription; these had been
sourced either at home (38% of total) or in Saudi Arabia (32% of
total).148 Pilgrims generally take antimicrobials to prevent or treat
respiratory infections (including likely viral infections) or to
prevent diarrhoeal disease. The Infectious Diseases Society of
America has speciﬁcally advised against the use of prophylactic
antibiotics for travellers’ diarrhoea due to increasing resistance
among microorganisms and the rise in opportunistic pathogens
such as Clostridium difﬁcile.149
Relatively little is known about the AMR status of bacteria
circulating during pilgrimages. A large-scale study employing
integrated molecular and genomic approaches to evaluate the
prevalence of antimicrobial resistance at Hajj and the impact of
antimicrobial misuse on the structure of circulating respiratory
(e.g., N. meningitidis, S. pneumoniae) and enteric infectious agents
(e.g. Salmonella spp, Shigella spp, and E. coli) would be of great value.
There are few vaccines available for enteric infectious diseases.
However, sanitation, good hygiene behaviour (regular hand
washing and disinfectant use), and food security represent the
key measures to control Hajj-associated diarrhoeal diseases. Large-
scale controlled trials addressing the effectiveness of hand hygiene
practices in the Hajj setting would provide signiﬁcant additional
information.
4. The status of Hajj vaccination studies highlights the
knowledge gaps
The majority of recently published vaccine studies during Hajj
have focused on vaccination against inﬂuenza virus, S. pneumoniae,
and N. meningitidis,150 and have either assessed the awareness
of pilgrims of health procedures on departure,151,152 or have
evaluated the efﬁcacy of administered vaccines upon return.79,80
Recent pre-Hajj vaccine-related studies have measured pil-
grims’ knowledge, attitudes, and practice, with the results being
alarming and indicating a signiﬁcant continuing lack of Hajj
vaccination awareness among pilgrims. For instance, a study
conducted before the 2014 Hajj season among French pilgrims
(n = 300) found that only 25% of the pilgrims and their general
practitioners were aware of the availability of pneumococcal
vaccines.151Post-Hajj surveillance studies have often integrated both
clinical and demographic data along with laboratory diagnostic
approaches to characterize the prevalence of particular infections.
However, study designs and diagnostic approaches tend to vary
considerably from conventional culturing to molecular-based
approaches,75,79,153 making it challenging to compare the results
from different studies. The adoption of multiplexed molecular
diagnostics and genomic approaches would aid with the accuracy
and responsiveness of pathogen detection.
5. Comprehensive database to strengthen knowledge
dissemination
The advancements made in the sequencing technology and
bioinformatics tools used for data analysis have had a signiﬁcant
impact on different branches of medicine, particularly vaccinology.
For instance, reverse vaccinology approaches fuelled by the
abundance of high-throughput sequencing data have been used
successfully to develop a multicomponent N. meningitidis serotype
B vaccine (MenB, Bexsero) in a relatively short timeframe.154–156
This lends itself to a new big data effort to combine vaccine
efﬁcacy data with epidemiological, surveillance, and genomic data.
This could be done as part of a wider effort in mass gatherings
medicine to track infections using molecular epidemiology
approaches during the Hajj and Umrah pilgrimages. For example,
the Inﬂuenza Sequence Database launched in 2001 was one of the
earliest attempts in this context; it provides a specialized sequence
collection service devoted to surveillance and vaccine design.157
The Inﬂuenza Research Database (IRD),158 launched in response to
the 2009 inﬂuenza A pandemic, is another example; this integrates
epitopes, protein structures, single nucleotide polymorphisms
(SNPs), and epidemiological and surveillance data for more than
98 000 strains of inﬂuenza virus. Similarly, Vaxjo,159 a web-based
adjuvant database, is integrated within the previously established
vaccine information repository VIOLIN,160,161 and is used to
explore the role of adjuvants in vaccine efﬁcacy and development.
For the Hajj setting, a more comprehensive database to gather
data from different healthcare perspectives (epidemiological,
surveillance, primary and secondary care) is crucial. Such a database
would help to orchestrate and centralize the efforts of health
ofﬁcials of both Saudi Arabia and the countries of origin of the
pilgrims. Maintaining such a database would help in the real-time
detection of public health issues to allow for the timely implemen-
tation of new policies or the review/improvement of current policies.
The Saudi Ministry of Health in collaboration with the US
Centers for Disease Control and Prevention has implemented the
latest technologies in data gathering.162 This is part of a much
larger effort that has been undertaken in developing a compre-
hensive healthcare surveillance network that is monitoring all
communicable diseases during Hajj.163 These advances in infor-
mation and communications technologies can aid in data
gathering and in turn can be used to deliver public health
messages to the pilgrims (e.g., the personal protective equipment
to be used). A pilot study conducted during the 2014 Hajj season
used smartphone applications to collect health-related data
(pilgrim health behaviour and awareness and compliance with
protective measures).164 The implementation of this approach on
a large scale would assist in the real-time monitoring of the status
of infectious disease transmission during mass gatherings.
6. Conclusions
The available data demonstrate that the current vaccination
policy contributes towards controlling the transmission of infec-
tious diseases during the unique mass gathering setting of the Hajj
pilgrimage. However, key vaccine-related aspects require further
M. Abd El Ghany et al. / International Journal of Infectious Diseases 47 (2016) 29–37 35investigation (Table 2). These include insufﬁcient data on the
burden of vaccine-preventable disease during the Hajj pilgrimage,
feasibility studies for the introduction of new mandatory vaccines,
effectiveness of new available vaccines among different age groups
and extremely diverse ethnic populations, the development of a
ﬁnal Hajj vaccination schedule, timing of vaccination relative to the
pilgrimage, the potential impact of widespread vaccine usage on
selection pressures, low vaccine coverage among pilgrims, syner-
gistic effects of other preventive measures, simple tools to deliver
public health messages, and novel tools to gather data and
disseminate knowledge. Investigations of the above-mentioned
aspects require the design of large-scale studies employing
multidisciplinary and high-throughput approaches. This should
be coupled with the establishment and maintenance of compre-
hensive databases to gather and disseminate data from different
healthcare perspectives.
Conﬂict of interest: The authors declare that there is no conﬂict
of interest or funding.
References
1. Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet 2006;367:
1008–15.
2. World Health Organization. World Bank. State of the world’s vaccines and
immunization, 3rd ed., Geneva: WHO; 2009.
3. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination
greatly reduces disease, disability, death and inequity worldwide. Bull World
Health Organ 2008;86:140–6.
4. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibi-
otic resistance. Lancet Infect Dis 2008;8:785–95.
5. Cohen R. Approaches to reduce antibiotic resistance in the community. Pediatr
Infect Dis J 2006;25:977–80.
6. Kwong JC, Maaten S, Upshur RE, Patrick DM, Marra F. The effect of universal
inﬂuenza immunization on antibiotic prescriptions: an ecological study. Clin
Infect Dis 2009;49:750–6.
7. Siegrist CA. Vaccine immunology. In: VaccinesSixth, Elsevier; 2013: 14–32.
8. Memish ZA, Al Rabeeah AA. Health conditions for travellers to Saudi Arabia for
the Umra and pilgrimage to Mecca (Hajj)—2014. J Epidemiol Glob Health
2014;4:73–5.
9. WHO. Health conditions for travellers to Saudi Arabia for the pilgrimage to
Mecca (Hajj), 2015. Wkly Epidemiol Rec 2015;90(31):381–92.
10. International Travel and Health, WHO, ITH. International travel and health.
Geneva: WHO; 2015, Available at: http://www.who.int/ith/en/ (accessed
10 May 2016)
11. Maiden MC. The impact of protein-conjugate polysaccharide vaccines: an
endgame for meningitis? Philos Trans R Soc Lond B Biol Sci 2013;368:20120147.
12. Funk A, Uadiale K, Kamau C, Caugant DA, Ango U, Greig J. Sequential outbreaks
due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria,
2013–14. PLoS Curr 2014;6.
13. Delrieu I, Yaro S, Tamekloe TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, et al.
Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo
and Burkina Faso. PLoS One 2011;6:e19513.
14. Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningo-
coccal disease in Africa: need for a vaccine. Vaccine 2013;31:2852–61.
15. Swartley JS, Marﬁn AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule
switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997;94:271–6.
16. Beddek AJ, Li MS, Kroll JS, Jordan TW, Martin DR. Evidence for capsule switch-
ing between carried and disease-causing Neisseria meningitidis strains. Infect
Immun 2009;77:2989–94.
17. Golubchik T, Brueggemann AB, Street T, Gertz Jr RE, Spencer CC, Ho T, et al.
Pneumococcal genome sequencing tracks a vaccine escape variant formed
through a multi-fragment recombination event. Nat Genet 2012;44:352–5.
18. Xu Y, Liu B, Grondahl-Yli-Hannuksila K, Tan Y, Feng L, Kallonen T, et al. Whole-
genome sequencing reveals the effect of vaccination on the evolution of
Bordetella pertussis. Sci Rep 2015;5:12888.
19. Day T, Galvani A, Struchiner C, Gumel A. The evolutionary consequences of
vaccination. Vaccine 2008;26(Suppl 3):C1–3.
20. Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrob
Agents 2003;21:102–6.
21. Moore PS, Reeves MW, Schwartz B, Gellin BG, Broome CV. Intercontinental
spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989;2:
260–3.
22. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain
of Neisseria meningitidis serogroup W135: estimates of the attack rate in a
deﬁned population and the risk of invasive disease developing in carriers. Clin
Infect Dis 2003;36:679–83.
23. Aguilera JF, Perrocheau A, Meffre C, Hahne S, Group WW. Outbreak of ser-
ogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.
Emerg Infect Dis 2002;8(8):761–7.24. Jones DM, Sutcliffe EM. Group A meningococcal disease in England associated
with the Haj. J Infect 1990;21:21–5.
25. Klaber R, Booy R, El Bashir H, Mifsud A, Taylor S. Sustained outbreak of W135
meningococcal disease in east London, UK. Lancet 2002;360:644.
26. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in
the UK. J Med Microbiol 2002;51:717–22.
27. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of
meningococcal serogroup C conjugate vaccine 4 years after introduction.
Lancet 2004;364:365–7.
28. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons
learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines
2009;8:851–61.
29. Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, et al. Effect of a
quadrivalent meningococcal ACWY glycoconjugate or a serogroup B menin-
gococcal vaccine on meningococcal carriage: an observer-blind, phase 3 ran-
domised clinical trial. Lancet 2014;384:2123–31.
30. Ridda I, King C, Rashid H. Pneumococcal infections at Hajj: current knowledge
gaps. Infect Disord Drug Targets 2014;14:177–84.
31. El-Sheikh SM, El-Assouli SM, Mohammed KA, Albar M. Bacteria and viruses
that cause respiratory tract infections during the pilgrimage (Haj) season in
Makkah, Saudi Arabia. Trop Med Int Health 1998;3:205–9.
32. Baharoon S, Al-Jahdali H, Al Hashmi J, Memish ZA, Ahmed QA. Severe sepsis
and septic shock at the Hajj: etiologies and outcomes. Travel Med Infect Dis
2009;7:247–52.
33. Asghar AH, Ashshi AM, Azhar EI, Bukhari SZ, Zafar TA, Momenah AM. Proﬁle of
bacterial pneumonia during Hajj. Indian J Med Res 2011;133:510–3.
34. Memish ZA, Almasri M, Turkestani A, Al-Shangiti AM, Yezli S. Etiology of severe
community-acquired pneumonia during the 2013 Hajj—part of the MERS-CoV
surveillance program. Int J Infect Dis 2014;25:186–90.
35. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al.
Burden of disease caused by Streptococcus pneumoniae in children younger
than 5 years: global estimates. Lancet 2009;374(9693):893–902.
36. McCullers JA, Rehg JE. Lethal synergism between inﬂuenza virus and Strepto-
coccus pneumoniae: characterization of a mouse model and the role of platelet-
activating factor receptor. J Infect Dis 2002;186:341–50.
37. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S,
et al. IL-10 is an important mediator of the enhanced susceptibility to
pneumococcal pneumonia after inﬂuenza infection. J Immunol 2004;172:
7603–9.
38. Kukavica-Ibrulj I, Hamelin ME, Prince GA, Gagnon C, Bergeron Y, Bergeron MG,
et al. Infection with human metapneumovirus predisposes mice to severe
pneumococcal pneumonia. J Virol 2009;83:1341–9.
39. Shrestha S, Foxman B, Berus J, van Panhuis WG, Steiner C, Viboud C, et al. The
role of inﬂuenza in the epidemiology of pneumonia. Sci Rep 2015;5:15314.
40. World Health Organization. 23-valent pneumococcal polysaccharide vaccine.
WHO position paper. Wkly Epidemiol Rec 2008;83:373–84.
41. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal
conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for
adults with immunocompromising conditions: recommendations of the Ad-
visory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly
Rep 2012;61:816–9.
42. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al.,
Centers for Disease Control and Prevention. Use of 13-valent pneumococcal
conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine
among adults aged 65 years: recommendations of the Advisory Committee
on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:
822–5.
43. Leinonen M, Sakkinen A, Kalliokoski R, Luotonen J, Timonen M, Makela PH.
Antibody response to 14-valent pneumococcal capsular polysaccharide vac-
cine in pre-school age children. Pediatr Infect Dis 1986;5:39–44.
44. Koskela M, Leinonen M, Haiva VM, Timonen M, Makela PH. First and second
dose antibody responses to pneumococcal polysaccharide vaccine in infants.
Pediatr Infect Dis 1986;5:45–50.
45. Baltimore RS. New challenges in the development of a conjugate pneumococ-
cal vaccine. JAMA 1992;268:3366–7.
46. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The
protective efﬁcacy of polyvalent pneumococcal polysaccharide vaccine. N Engl
J Med 1991;325:1453–60.
47. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness
of 23-valent pneumococcal polysaccharide vaccine against invasive pneumo-
coccal disease in the elderly in England and Wales. Vaccine 2012;30:6802–8.
48. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, CAPITA Coauthors. et al.
Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J
Med 2003;348(18):1747–55.
49. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, et al.
Incremental effectiveness of pneumococcal vaccine on simultaneously ad-
ministered inﬂuenza vaccine in preventing pneumonia and pneumococcal
pneumonia among persons aged 65 years or older. Vaccine 1999;17:2493–500.
50. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efﬁcacy of pneumococcal
vaccination in adults: a meta-analysis. CMAJ 2009;180:48–58.
51. Mangtani P, Cutts F, Hall AJ. Efﬁcacy of polysaccharide pneumococcal vaccine
in adults in more developed countries: the state of the evidence. Lancet Infect
Dis 2003;3:71–8.
52. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing
pneumococcal infection in adults. Cochrane Database Syst Rev 2013;1:
CD000422.
M. Abd El Ghany et al. / International Journal of Infectious Diseases 47 (2016) 29–373653. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal
polysaccharide vaccines in adults: a systematic review of observational stud-
ies and comparison with results from randomised controlled trials. Vaccine
2004;22:3214–24.
54. Black S, Shineﬁeld H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efﬁcacy, safety
and immunogenicity of heptavalent pneumococcal conjugate vaccine in chil-
dren. Northern California Kaiser Permanente Vaccine Study Center Group.
Pediatr Infect Dis J 2000;19:187–95.
55. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al., Gambian
Pneumococcal Vaccine Trial Group. Efﬁcacy of nine-valent pneumococcal
conjugate vaccine against pneumonia and invasive pneumococcal disease
in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet
2005;365:1139–46.
56. Shineﬁeld HR, Black S. Efﬁcacy of pneumococcal conjugate vaccines in large
scale ﬁeld trials. Pediatr Infect Dis J 2000;19:394–7.
57. O’Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efﬁcacy
and safety of seven-valent conjugate pneumococcal vaccine in American
Indian children: group randomised trial. Lancet 2003;362:355–61.
58. Bonten MJ, Huijts SM, Bolkenbaas M, Coauthors C. Vaccine against pneumo-
coccal pneumonia in adults. N Engl J Med 2015;373:93.
59. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al.
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
N Engl J Med 2015;372:1114–25.
60. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, Vaccine
Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children
with and those without HIV infection. N Engl J Med 2003;349:1341–8.
61. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al.
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N
Engl J Med 2010;362:812–22.
62. Poehling KA, Talbot TR, Grifﬁn MR, Craig AS, Whitney CG, Zell E, et al. Invasive
pneumococcal disease among infants before and after introduction of pneu-
mococcal conjugate vaccine. JAMA 2006;295:1668–74.
63. Roca A, Hill PC, Townend J, Egere U, Antonio M, Bojang A, et al. Effects of
community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal
carriage in the Gambia: a cluster-randomized trial. PLoS Med 2011;8:
e1001107.
64. Andrade AL, Ternes YM, Vieira MA, Moreira WG, Lamaro-Cardoso J, Kipnis A,
et al. Direct effect of 10-valent conjugate pneumococcal vaccination on
pneumococcal carriage in children Brazil. PLoS One 2014;9:e98128.
65. Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al.
Population effect of 10-valent pneumococcal conjugate vaccine on nasopha-
ryngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus
inﬂuenzae in Kiliﬁ, Kenya: ﬁndings from cross-sectional carriage studies.
Lancet Glob Health 2014;2:e397–405.
66. Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A, et al.
Immunogenicity, impact on carriage and reactogenicity of 10-valent pneu-
mococcal non-typeable Haemophilus inﬂuenzae protein D conjugate vaccine
in Kenyan children aged 1-4 years: a randomized controlled trial. PLoS One
2014;9:e85459.
67. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants
emerge after pneumococcal vaccination in the United States. PLoS Pathog
2007;3:e168.
68. Beall B, McEllistrem MC, Gertz Jr RE, Wedel S, Boxrud DJ, Gonzalez AL, et al.,
Active Bacterial Core Surveillance Team. Pre- and postvaccination clonal
compositions of invasive pneumococcal serotypes for isolates collected in
the United States in 1999, 2001, and 2002. J Clin Microbiol 2006;44:999–1017.
69. Metzger DW, Furuya Y, Salmon SL, Roberts S, Sun K. Limited efﬁcacy of
antibacterial vaccination against secondary serotype 3 pneumococcal pneu-
monia following inﬂuenza infection. J Infect Dis 2015;212:445–52.
70. Mina MJ, Klugman KP, McCullers JA. Live attenuated inﬂuenza vaccine, but not
pneumococcal conjugate vaccine, protects against increased density and
duration of pneumococcal carriage after inﬂuenza infection in pneumococcal
colonized mice. J Infect Dis 2013;208:1281–5.
71. Haworth E, Barasheed O, Memish ZA, Rashid H, Booy R. Prevention of inﬂuenza
at Hajj: applications for mass gatherings. J R Soc Med 2013;106:215–23.
72. El Bashir H, Haworth E, Zambon M, Shaﬁ S, Zuckerman J, Booy R. Inﬂuenza
among U.K. pilgrims to Hajj, 2003. Emerg Infect Dis 2004;10:1882–3.
73. Balkhy HH, Memish ZA, Bafaqeer S, Almuneef MA. Inﬂuenza a common viral
infection among Hajj pilgrims: time for routine surveillance and vaccination.
J Travel Med 2004;11:82–6.
74. Rashid H, Shaﬁ S, Booy R, El Bashir H, Ali K, Zambon M, et al. Inﬂuenza and
respiratory syncytial virus infections in British Hajj pilgrims. Emerg Health
Threats J 2008;1:e2.
75. Rashid H, Shaﬁ S, Haworth E, El Bashir H, Memish ZA, Sudhanva M, et al. Viral
respiratory infections at the Hajj: comparison between UK and Saudi pilgrims.
Clin Microbiol Infect 2008;14:569–74.
76. Alborzi A, Aelami MH, Ziyaeyan M, Jamalidoust M, Moeini M, Pourabbas B,
et al. Viral etiology of acute respiratory infections among Iranian Hajj pilgrims,
2006. J Travel Med 2009;16:239–42.
77. Memish ZA, Assiri AM, Hussain R, Alomar I, Stephens G. Detection of respira-
tory viruses among pilgrims in Saudi Arabia during the time of a declared
inﬂuenza A(H1N1) pandemic. J Travel Med 2012;19:15–21.
78. Memish ZA, Assiri AM, Alshehri M, Hussain R, Alomar I. The prevalence of
respiratory viruses among healthcare workers serving pilgrims in Makkah
during the 2009 inﬂuenza A (H1N1) pandemic. Travel Med Infect Dis 2012;10:
18–24.79. Kandeel A, Deming M, Elkreem EA, El-Refay S, Aﬁﬁ S, Abukela M, et al.
Pandemic (H1N1) 2009 and Hajj pilgrims who received predeparture vacci-
nation, Egypt. Emerg Infect Dis 2011;17:1266–8.
80. Moattari A, Emami A, Moghadami M, Honarvar B. Inﬂuenza viral infections
among the Iranian Hajj pilgrims returning to Shiraz, Fars Province, Iran.
Inﬂuenza Other Respir Viruses 2012;6:e77–9.
81. Alfelali M, Barasheed O, Tashani M, Azeem MI, El Bashir H, Memish ZA, et al.,
Hajj Research Team. Changes in the prevalence of inﬂuenza-like illness and
inﬂuenza vaccine uptake among Hajj pilgrims: a 10-year retrospective analy-
sis of data. Vaccine 2015;33:2562–9.
82. Lee AJ, Das SR, Wang W, Fitzgerald T, Pickett BE, Aevermann BD, et al.
Diversifying selection analysis predicts antigenic evolution of 2009 pandemic
H1N1 inﬂuenza A virus in humans. J Virol 2015;89:5427–40.
83. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus
AD, et al. Mapping the antigenic and genetic evolution of inﬂuenza virus.
Science 2004;305:371–6.
84. Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V, Hay AJ, et al. Integrating
inﬂuenza antigenic dynamics with molecular evolution. Elife 2014;3:e01914.
85. Bhatt S, Lam TT, Lycett SJ, Leigh Brown AJ, Bowden TA, Holmes EC, et al.,
Combating Swine Inﬂuenza C, Pybus OG. The evolutionary dynamics of
inﬂuenza A virus adaptation to mammalian hosts. Philos Trans R Soc Lond B
Biol Sci 2013;368:20120382.
86. Drummond AJ, Ho SY, Phillips MJ, Rambaut A. Relaxed phylogenetics and
dating with conﬁdence. PLoS Biol 2006;4:e88.
87. Strelkowa N, Lassig M. Clonal interference in the evolution of inﬂuenza.
Genetics 2012;192:671–82.
88. Tharakaraman K, Sasisekharan R. Inﬂuenza surveillance: 2014–2015 H1N1
‘‘swine’’-derived inﬂuenza viruses from India. Cell Host Microbe 2015;17:
279–82.
89. Belanov SS, Bychkov D, Benner C, Ripatti S, Ojala T, Kankainen M, et al.
Genome-wide analysis of evolutionary markers of human inﬂuenza
A(H1N1)pdm09 and A(H3N2) viruses may guide selection of vaccine strain
candidates. Genome Biol Evol 2015;7(12):3472–83.
90. Broberg E, Snacken R, Adlhoch C, Beaute J, Galinska M, Pereyaslov D, et al.,
Region WHOE, the European Inﬂuenza Surveillance N. Start of the 2014/15
inﬂuenza season in Europe: drifted inﬂuenza A(H3N2) viruses circulate as
dominant subtype. Euro Surveill 2015;20(4). http://dx.doi.org/10.2807/1560-
7917.ES2015.20.4.21023
91. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA,
et al., Centers for Disease Control and Prevention. Early estimates of seasonal
inﬂuenza vaccine effectiveness—United States, January 2015. MMWR Morb
Mortal Wkly Rep 2015;64:10–5.
92. Rondy M, Launay O, Puig-Barbera J, Gefenaite G, Castilla J, de Gaetano Donati K,
et al., European hospital IVEn, Moren A. 2012/13 inﬂuenza vaccine effective-
ness against hospitalised inﬂuenza A(H1N1)pdm09, A(H3N2) and B: estimates
from a European network of hospitals. Euro Surveill 2015;20(2). http://
dx.doi.org/10.2807/1560-7917.ES2015.20.2.21011
93. Valenciano M, Kissling E, Reuss A, Jimenez-Jorge S, Horvath JK, Donnell JM, et al.
The European I-MOVE Multicentre 2013-2014 Case–Control Study. Homoge-
neous moderate inﬂuenza vaccine effectiveness against A(H1N1)pdm09 and
heterogeneous results by country against A(H3N2). Vaccine 2015;33:2813–22.
94. Alfelali M, Khandaker G, Booy R, Rashid H. Mismatching between circulating
strains and vaccine strains of inﬂuenza: effect on Hajj pilgrims from both
hemispheres. Hum Vaccin Immunother 2016;12(3):709–15.
95. Cao W, Kim JH, Chirkova T, Reber AJ, Biber R, Shay DK, et al. Improving
immunogenicity and effectiveness of inﬂuenza vaccine in older adults. Expert
Rev Vaccines 2011;10:1529–37.
96. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, et al. Half- vs
full-dose trivalent inactivated inﬂuenza vaccine (2004–2005): age, dose, and
sex effects on immune responses. Arch Intern Med 2008;168:2405–14.
97. Frenck Jr RW, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al.
Comparison of the immunogenicity and safety of a split-virion, inactivated,
trivalent inﬂuenza vaccine (Fluzone(R)) administered by intradermal and
intramuscular route in healthy adults. Vaccine 2011;29:5666–74.
98. DiazGranados CA, Saway W, Gouaux J, Baron M, Baker J, Denis M, et al. Safety
and immunogenicity of high-dose trivalent inactivated inﬂuenza vaccine in
adults 50-64 years of age. Vaccine 2015;33(51):7188–93.
99. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, et al. Safety and
immunogenicity of a high dosage trivalent inﬂuenza vaccine among elderly
subjects. Vaccine 2007;25:7656–63.
100. DiazGranados CA, Dunning AJ, Jordanov E, Landolﬁ V, Denis M, Talbot HK.
High-dose trivalent inﬂuenza vaccine compared to standard dose vaccine in
elderly adults: safety, immunogenicity and relative efﬁcacy during the 2009-
2010 season. Vaccine 2013;31:861–6.
101. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-
blind controlled phase 3 trial comparing the immunogenicity of high-dose and
standard-dose inﬂuenza vaccine in adults 65 years of age and older. J Infect Dis
2009;200:172–80.
102. Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, et al.
Immunogenicity and safety of Fluzone((R)) intradermal and high-dose inﬂu-
enza vaccines in older adults 65 years of age: a randomized, controlled,
phase II trial. Vaccine 2014;32:2507–17.
103. Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, et al. Progress on
adenovirus-vectored universal inﬂuenza vaccines. Hum Vaccin Immunother
2015;11:1209–22.
M. Abd El Ghany et al. / International Journal of Infectious Diseases 47 (2016) 29–37 37104. Price GE, Lo CY, Misplon JA, Epstein SL. Mucosal immunization with a candi-
date universal inﬂuenza vaccine reduces virus transmission in a mouse model.
J Virol 2014;88:6019–30.
105. Garcia M, Misplon JA, Price GE, Lo CY, Epstein SL. Age dependence of immunity
induced by a candidate universal inﬂuenza vaccine in mice. PLoS One 2016;11:
e0153195.
106. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts
the morbidity and mortality associated with inﬂuenza. Nature 2012;484:
519–23.
107. Johnson DF, Leder K, Torresi J. Hepatitis B and C infection in international
travelers. J Travel Med 2013;20:194–202.
108. Memish ZA, Venkatesh S, Ahmed QA. Travel epidemiology: the Saudi perspec-
tive. Int J Antimicrob Agents 2003;21:96–101.
109. Gatrad AR, Sheikh A. Hajj and risk of blood borne infections. Arch Dis Child
2001;84:375.
110. Raﬁq SM, Rashid H, Haworth E, Booy R. Hazards of hepatitis at the Hajj. Travel
Med Infect Dis 2009;7:239–46.
111. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B
virus infection: new estimates of age-speciﬁc HBsAg seroprevalence and
endemicity. Vaccine 2012;30:2212–9.
112. Mohd Hanaﬁah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology
of hepatitis C virus infection: new estimates of age-speciﬁc antibody to HCV
seroprevalence. Hepatology 2013;57:1333–42.
113. El Beltagy KE, Al Balawi IA, Almuneef M, Memish ZA. Prevalence of hepatitis B
virus markers among blood donors in a tertiary hospital in Tabuk, northwest-
ern Saudi Arabia. Int J Infect Dis 2008;12:495–9.
114. Mahaba H, el-Tayeb Ael K, Elbaz H. The prevalence of antibodies to hepatitis C
virus in Hail region, Saudi Arabia. J Egypt Public Health Assoc 1999;74:69–80.
115. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of world-
wide prevalence of chronic hepatitis B virus infection: a systematic review of
data published between 1965 and 2013. Lancet 2015;386:1546–55.
116. World Health Organization. Hepatitis A vaccines. WHO position paper. Wkly
Epidemiol Rec 2000;75:38–42.
117. World Health Organization. WHO position paper on hepatitis A vaccines—June
2012. Wkly Epidemiol Rec 2012;87:261–76.
118. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection:
epidemiology and vaccination. Epidemiol Rev 2006;28:112–25.
119. World Health Organization. Hepatitis B vaccines: WHO position paper—
recommendations. Vaccine 2010;28:589–90.
120. Vryheid RE, Kane MA, Muller N, Schatz GC, Bezabeh S. Infant and adolescent
hepatitis B immunization up to 1999: a global overview. Vaccine 2000;19:
1026–37.
121. Infectious diseases related to travel—hepatitis B. 2011. http://wwwnc.cdc.
gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-
to-travel/hepatitis-b.htm (accessed 10 May 2016).
122. World Health Organization. International travel and health. Geneva: WHO;
2012, Available at: http://www.who.int/ith/en/ (accessed 10 May 2016)
123. Zuckerman JN, Van Damme P, Van Herck K, Loscher T. Vaccination options for
last-minute travellers in need of travel-related prophylaxis against hepatitis
A and B and typhoid fever: a practical guide. Travel Med Infect Dis 2003;1:
219–26.
124. Ghadiri K, Vaziri S, Afsharian M, Jahanbaksh A, Mansouri F, Sayad M, et al.
Comparison of the accelerated and standard vaccination schedules against
hepatitis B in healthcare workers. J Res Med Sci 2012;17:934–7.
125. Van Herck K, Leuridan E, Van Damme P. Schedules for hepatitis B vaccination
of risk groups: balancing immunogenicity and compliance. Sex Transm Infect
2007;83:426–32.
126. Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines: a review
of their immunogenicity and tolerability. Drugs 2003;63:2625–49.
127. Wolters B, Muller T, Ross RS, Clauberg R, Werfel U, Roggendorf H, et al.
Comparative evaluation of the immunogenicity of combined hepatitis A
and B vaccine by a prospective and retrospective trial. Hum Vaccin 2009;5:
248–53.
128. Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM, Centers for Disease
Control and Prevention. Update on vaccine-derived polioviruses—worldwide,
January 2014–March 2015. MMWR Morb Mortal Wkly Rep 2015;64:640–6.
129. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect
Dis 2014;210(Suppl 1):S283–93.
130. Polio Eradication & Endgame Midterm Review. 2015. Available at: http://
www.polioeradication.org (accessed 10 May 2016).
131. Hagan JE, Wassilak SG, Craig AS, Tangermann RH, Diop OM, Burns CC, et al.,
Centers for Disease Control and Prevention. Progress toward polio eradica-
tion—worldwide, 2014–2015. MMWR Morb Mortal Wkly Rep 2015;64:527–31.
132. Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, et al., Centers for
Disease Control and Prevention. Possible eradication of wild poliovirus type
3—worldwide, 2012. MMWR Morb Mortal Wkly Rep 2014;63:1031–3.
133. World Health Organization. Global vaccine action plan 2011–2020. Geneva:
WHO; 2013, Available at: http://www.who.int (accessed 10 May 2016)
134. World Health Organization. Replacing trivalent OPV with bivalent OPV.
Geneva WHO. 2015, Available at: http://www.who.int/immunization/
diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/en/ (accessed
10 May 2016).
135. Initiative GPE. Response to type 2 vaccine-derived polioviruses prior to global
tOPV withdrawal. Interim guidelines. 2015. Available at: http://www.
polioeradication.org/Resourcelibrary/Resourcesforpolioeradicators.aspx
(accessed 10 May 2016).136. Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field
trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.
Lancet 1990;335:270–3.
137. Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, Cabezas C, et al.
Protective efﬁcacy of oral whole-cell/recombinant-B-subunit cholera vaccine
in Peruvian military recruits. Lancet 1994;344:1273–6.
138. Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, et al.
Effectiveness of an oral cholera vaccine in Zanzibar: ﬁndings from a mass
vaccination campaign and observational cohort study. Lancet Infect Dis
2012;12:837–44.
139. Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, et al.
Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl
J Med 2005;352:757–67.
140. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. Use of Vibrio
cholerae vaccine in an outbreak in Guinea. N Engl J Med 2014;370:2111–20.
141. Clemens JD, Sack DA, Rao MR, Chakraborty J, Khan MR, Kay B, et al. Evidence
that inactivated oral cholera vaccines both prevent and mitigate Vibrio cho-
lerae O1 infections in a cholera-endemic area. J Infect Dis 1992;166:1029–34.
142. Black RE, Levine MM, Clements ML, Young CR, Svennerholm AM, Holmgren J.
Protective efﬁcacy in humans of killed whole-Vibrio oral cholera vaccine with
and without the B subunit of cholera toxin. Infect Immun 1987;55:1116–20.
143. Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet
Infect Dis 2006;6:361–73.
144. Lewnard JA, Antillon M, Gonsalves G, Miller AM, Ko AI, Pitzer VE. Strategies to
prevent cholera introduction during international personnel deployments: a
computational modeling analysis based on the 2010 Haiti outbreak. PLoS Med
2016;13:e1001947.
145. Enzler MJ, Berbari E, Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin
Proc 2011;86:686–701.
146. World Health Organization. Antimicrobial resistance: global report on sur-
veillance 2014. Geneva: WHO; 2014, doi: 978 92 4 156474 8, http://www.
who.int/drugresistance/documents/surveillancereport/en/
147. Olaitan AO, Dia NM, Gautret P, Benkouiten S, Belhouchat K, Drali T, et al.
Acquisition of extended-spectrum cephalosporin- and colistin-resistant Sal-
monella enterica subsp. enterica serotype Newport by pilgrims during Hajj. Int J
Antimicrob Agents 2015;45:600–4.
148. Azeem M, Tashani M, Barasheed O, Heron L, Hill-Cawthorne GA, Haworth E, et al.
Knowledge, Attitude and Practice (KAP) survey concerning antimicrobial use
among Australian Hajj pilgrims. Infect Disord Drug Targets 2014;14(2):125–32.
149. Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE,
et al., Infectious Diseases Society of America. The practice of travel medicine:
guidelines by the Infectious Diseases Society of America. Clin Infect Dis
2006;43:1499–539.
150. Alqahtani AS, Alfelali M, Arbon P, Booy R, Rashid H. Burden of vaccine
preventable diseases at large events. Vaccine 2015;33(48):6552–63.
151. Sridhar S, Belhouchat K, Drali T, Benkouiten S, Parola P, Brouqui P, et al. French
Hajj pilgrims’ experience with pneumococcal infection and vaccination: a
knowledge, attitudes and practice (KAP) evaluation. Travel Med Infect Dis
2015;13:251–5.
152. Alqahtani AS, Sheikh M, Wiley K, Heywood AE. Australian Hajj pilgrims’
infection control beliefs and practices: insight with implications for public
health approaches. Travel Med Infect Dis 2015;13:329–34.
153. Aberle JH, Popow-Kraupp T, Kreidl P, Laferl H, Heinz FX, Aberle SW. Inﬂuenza A
and B viruses but not MERS-CoV in Hajj pilgrims, Austria, 2014. Emerg Infect
Dis 2015;21:726–7.
154. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of
genomics. Immunity 2010;33:530–41.
155. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, et al.
Diversity of Canadian meningococcal serogroup B isolates and estimated
coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
Vaccine 2013;32:124–30.
156. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted
strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Eur-
ope: a qualitative and quantitative assessment. Lancet Infect Dis 2013;13:416–25.
157. Macken C, Lu H, Goodman J, Broykin LM. The value of a database in surveil-
lance and vaccine selection. International Congress Series 2001;10:103–6.
158. Squires RB, Noronha J, Hunt V, Garcia-Sastre A, Macken C, Baumgarth N, et al.
Inﬂuenza research database: an integrated bioinformatics resource for inﬂu-
enza research and surveillance. Inﬂuenza Other Respir Viruses 2012;6:404–16.
159. Sayers S, Ulysse G, Xiang Z, He Y. Vaxjo: a web-based vaccine adjuvant
database and its application for analysis of vaccine adjuvants and their uses
in vaccine development. J Biomed Biotechnol 2012;2012:831486.
160. Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, et al. VIOLIN: vaccine
investigation and online information network. Nucleic Acids Res 2008;36:D923–8.
161. He Y, Racz R, Sayers S, Lin Y, Todd T, Hur J, et al. Updates on the web-based
VIOLIN vaccine database and analysis system. Nucleic Acids Res 2014;42:
D1124–32.
162. Li W. Implementation of a mobile-based surveillance system in Saudi Arabia
for the 2009 Hajj. Online J Public Health Inform 2013;5(1):137.
163. Memish ZA, Zumla A, Alhakeem RF, Assiri A, Turkestani A, Al Harby KD, et al.
Hajj: infectious disease surveillance and control. Lancet 2014;383:2073–82.
164. Alqahtani AS, BinDhim NF, Tashani M, Willaby HW, Wiley KE, Heywood AE,
et al. Pilot use of a novel smartphone application to track traveller health
behaviour and collect infectious disease data during a mass gathering: Hajj
pilgrimage 2014. J Epidemiol Glob Health 2015 2015. http://dx.doi.org/10.1016/
j.jegh.2015.07.005
